Business Standard

Margin improvement holds key for Lupin with US sales likely to soften

Go ahead for inhaler launch in the US and resolution of plant compliance issues are other triggers


Going ahead, US sales which grew sequentially however may soften in the June quarter, feel analysts.

Ujjval Jauhari
Lupin’s better-than-expected operational performance in March quarter was led by key markets of India and the US. The Indian market, which accounts for 13 per cent of revenues, grew an impressive 13.3 per cent year-on-year as compared to the 9-11 per cent registered by peers. While sales in the US market were expected to decline given higher base in the year ago quarter, the drop was lower than expected. North America, its single largest market contributing 42 per cent to sales, declined 9.3 per cent year-on-year. Motilal Oswal Financial Services had anticipated a sales decline of 10 per cent.


Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: May 30 2020 | 3:40 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on are available only to BS Premium subscribers.

Register to